Plus Therapeutics Q3 EPS $(1.00) Vs $(2.85) Last Year, Sales $1.24M Miss $1.29M Estimate
Portfolio Pulse from Benzinga Newsdesk
Plus Therapeutics reported Q3 losses of $(1.00) per share, a 64.91% increase over losses of $(2.85) per share from the same period last year. The company's quarterly sales of $1.24 million missed the analyst consensus estimate of $1.29 million by 3.88%, but showed a 1.60K% increase over sales of $73.00 thousand the same period last year.
October 31, 2023 | 8:06 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Plus Therapeutics reported a YoY increase in losses but also a significant increase in sales. However, the sales missed the analyst consensus estimate.
The company's losses have increased year over year, which is generally a negative sign. However, the significant increase in sales could be seen as a positive sign, despite missing the analyst consensus estimate. The net impact on the stock price is uncertain.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100